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Abstract
Purpose: The aim of this study was to evaluate the fluence for midline and lateralized tumors for volumetric modulated arc
therapy (VMAT) by using a two-dimensional array. Methods: For this study, we selected 60 patients who were undergoing
VMAT. The octavius phantom was computed tomography (CT) scanned and imported to the planning system. Verification
plans were created for each plan and exported. The measurements were performed using 2D seven29 ion chamber array. Flu-
ence measurement values for all the delivered plans were analyzed using VeriSoft software. The TPS calculated values were
then compared with the measured gamma values. Results: The gamma pass percentage for midline tumors was found to be
higher than that for lateralized tumors. The standard deviations between the gamma values for midline and lateralized tumors
were 1.96 and 2.86, respectively. Moreover, the standard deviations between the point doses for midline and lateralized tumors
were 0.360 and 0.283, respectively. The mean gamma passing rate was 96.96% for midline tumors and 96.57% for lateralized
tumors for 3%DD/3-mm criteria. There is no significance found in the gamma values for midline and lateralized tumors with
p-value 0.08. Conclusion: No particular correlation was found between the gamma pass percentage for midline tumors and that
for lateralized tumors. Only a marginal difference was found in the gamma pass percentage.
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Introduction
The advantage of nonuniform conformal beams to target
while sparing normal tissue has improved clinical outcome.
Reducing the side effects to the nontarget organs permits
tumor dose escalation and improves tumor control. The
concept of volumetric modulated arc therapy (VMAT) was
first proposed in 1995. VMAT is distinguished from intensity
modulated radiation therapy (IMRT) in modulated fluence is
achieved by a variable gantry speed, dose rate, and multileaf
collimator (MLC) movements.
In this technique, the gantry moves continuously around the
patient while the radiation is on. During rotation, the treat-
ment field is also dynamically changed by the MLC move-
ment. The success of intensity-modulated radiation delivery
depends on the performance of the MLC, and its speed and
position. Implementation of intensity-modulated beams has a
complex dose distribution and a distinct advantage to the
patient. Therefore, its application should be clinically vali-
dated. Historically, because of its complexity, IMRT plans
have been dosimetrically verified in a phantom before
treatment. Every patient plan is copied to the phantom ge-
ometry, and the dose is calculated from the treatment plan-
ning system (TPS). The measured distribution is compared
with the TPS-calculated distribution. TLD chips, diodes,
films, and so on provide accurate measurement of dose dis-
tribution.
A patient-specific quality assurance (QA) procedure has also
been implemented for VMAT. Quantitative analysis of pa-
tient-specific QA measurements is often used to determine
whether the delivered field is appropriate for treating the
patient. For point dose measurements, the percentage dif-
ference between the measured and planned doses is utilized.
For planar dose measurements, a combination of the percent
dose difference and distance to agreement (DTA) is typically
used to reduce the analysis to a single metric.
For a stringent method of evaluating the dose calculated by
using the TPS and the measured dose, a quantitative tool
called gamma analysis (γ) was developed by Low et al.1 This
tool was initially developed by Harms et al.2 As an extension
to the technique, Depuydt et al.3 and Low et al.4 proposed a
metric called a gamma value that combines absorbed-dose
difference and DTA criteria in a continuous distribution. The
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gamma value is a measure of how closely the calculated dis-
tribution matches the measured distribution, at a given
measurement point. The gamma value will increase with
DTA and the absorbed-dose difference between the measured
and calculated values. The measurement is the reference
information, and the calculated distribution is queried for
comparison.5 It measures the closest distance between each
reference point and the evaluated dose distribution after
scaling by dose difference (ΔD) and distance to agreement
(Δd). The dose difference and DTA evaluations complement
each other when used as determinants of agreement accuracy
between the dose maps.6 This study aimed to evaluate the
difference between the gamma values for midline tumors and
those for lateralized tumors, and the effect of MLC movement
on the pass percentage.
Methods and Materials
For this study, we selected 60 patients (which include 30
midline cases and 30 lateralized cases) who were undergoing
VMAT. This includes medial and lateral tumors. Medial tu-
mors refer to those situated at the midline of the body, and
lateral tumors refer to those located toward the side or away
from the midline of the body. Octavius computed tomogra-
phy (CT) phantom was CT scanned and imported to the
Eclipse version 10 TPS (Varian Medical Systems, Palo Alto,
CA). Verification plans for midline and lateralized tumors
were created separately by using the Varian Eclipse TPS with
the 2D Seven29 detector array and the Octavius phantom
(PTW, Freiburg, Germany).
The octavius phantom
The 2D Seven29 detector array system (PTW) comprises of an
Octavius phantom (PTW), array interface, 2D Seven29 de-
tector array, and software to obtain the data from the detec-
tor. The Octavius phantom used in this study is a dedicated
phantom for QA of rotational treatments that focus primarily
on the use of the Seven29 detector array. An octagonal shape
was chosen to allow data acquisition in multiple planes with
an easy phantom setup. It is made of polystyrene, with a
physical density of 1.04g/cm3, a width of 32 cm, and a length
of 32 cm. The bottom part of the phantom is removable and
can accommodate a CT base or a linear accelerator (LINAC)
base. The LINAC base has an air cavity to compensate for the
reduced response when irradiated from the posterior side. A
30  30  2.2 cm3 central cavity allows inserting the ion
chamber array into the phantom. The position of the cavity is
such that when the 2D array is inserted, the plane through
the middle of the ion chambers goes through the center of the
phantom.4
2D ion chamber array
The 2D-array Seven29 device is a two-dimensional detector
array (5.4 kg) consisting of 729 cubic vented ionization
chambers (0.5  0.5  0.5 cm3 each) arranged in a 27  27
matrix with a center-to-center spacing of 10 mm2.The
chambers are separated from each other by a 5-mm gap4. The
upper electrode layer is positioned below a 0.5-cm poly
(methyl methacrylate) (PMMA) build-up layer .The lower
electrode layer lies on top of a 2-mm thick electrode plate,
which is again mounted on a 10-mm PMMA base plate. The
5- and 10-mm PMMA layers have a water equivalent thick-
ness of 0.59 and 1.18 cm, respectively. The measurement
ranges for the PTW 2D array is 200–1000 Gy and 8-500
Gy/min. The 2D array is calibrated for absolute dosimetry in a
60-Co photon beam at the PTW secondary standard dosime-
try laboratory.5
Pretreatment QA
After the calculations, the verification plans for each patient
was exported. Figure 1(a) shows the verification plan created
for a patient with tumor at midline, and Figure1 (b) shows the
verification plan created for lateralized tumors. Measure-
ments were performed on a Varian Clinac 2100 iX, LINAC
(Varian Medical Systems, Palo Alto, CA) equipped with a
millennium 120-leaf collimator. The energy used was 6MV,
at a dose rate of 600MU/min. Verification plans for midline
and lateralized tumors were separately delivered. The fluence
measurements for all the delivered plans were analyzed by
using the VeriSoft software (PTW). A gamma criterion of 3%
dose difference and 3-mm DTA has been used to evaluate the
results. The TPS-calculated values were then compared with
the measured gamma values. The point doses were also eval-
uated.7
Gamma analysis
Gamma analysis is a method for comparing two dose distri-
butions. Dose difference and DTA are two parameters used in
the assessment of dose distribution. A parameter that takes
both dose deviation and DTA is the gamma index (γ).8 Figure
2(a) shows the gamma analysis using VeriSoft for the
TPS-calculated and array measurement values for midline
tumors, and Figure 2(b) shows the analysis for lateralized
tumors. The dose distribution comparison is subdivided into
regions of high dose gradients and low dose gradients, each
with different acceptance criteria. In the low-gradient re-
gions, the doses are compared directly, with an acceptance
tolerance placed on the difference between the measured and
calculated doses. Since the dose difference in the high-dose
gradient regions may be misleading, the concept of DTA is
used. DTA is the reference data point and the nearest point in
the compared dose distribution.3
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FIG. 1(a): Verification plans created for each patient for midline tumor.
FIG. 1(b): Verification plans created for each patient for midline tumor for lateralized tumor.
FIG. 2(a): The measured and calculated fluence for midline tumors were analysed using Verisoft Software, (PTW, Freiburg, Germany).
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FIG. 2(b): The measured and calculated fluence for lateralized tumors were analyzed using Verisoft Software, (PTW, Freiburg, Germany).
Results
Previously, various studies have been conducted on 2D array
by different authors.9-17 However; a clinical evaluation for the
gamma analysis of midline and lateralized tumors has not
been studied until now. The gamma pass percentage for mid-
line tumors was found to be higher than that for lateralized
tumors. The standard deviations between the gamma values
for midline tumors and those for lateralized tumors were 1.96
and 2.86, respectively. Moreover, the standard deviations
between the point doses for midline and lateralized tumors
were 0.360 and 0.283, respectively.
The average gamma passing rate was 96.96% for midline
tumors and 96.57% for lateralized tumors for the 3%/3-mm
criteria. The percentage variations for the midline and lat-
eralized cases are shown in Figure 3(a) and (b). The Student
t-test results showed no significant difference between the
gamma pass percentage for midline tumors and that for lat-
eralized tumors with p = 0.08. For point doses, the Student t-
test was performed to compare between the TPS-calculated
and measurement values. For midline and lateralized tumors,
the p-values were 0.48 and 0.47, respectively, indicating no
statistically significant difference. Figure 4 shows the per-
centage variation for (a) midline and (b) lateralized tumors.
The discrepancy in the values obtained from the TPS calcu-
lation and array measurements may be due to the error dur-
ing the entire process, such as errors in calculation, dosimet-
ric measurement, and during delivery. The results showed
that the pass percentage was slightly higher for midline tu-
mors than for the lateralized ones. The gamma pass percent-
age, which is delivered by using the partial arc technique, was
higher for lateralized tumors than for full-arc delivery. In
addition, the standard deviation between the point doses was
greater for midline tumors than for lateralized tumors. The
average gamma pass percentage was almost the same for
midline and lateralized tumors, according to the 3% DD and
3-mm pass criteria.
FIG. 3(a): Figure showing the gamma pass percentage for lateralized
tumors.
FIG. 3(b): Figure showing the gamma pass percentage for midline
tumors.
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FIG. 4(a): Figure showing the percentage variation between TPS
calculation and array measurement for midline tumors.
Figure 4(b): Figure showing the percentage variation between TPS
calculation and array measurement for lateralized tumors.
Discussion
From the results obtained, only a slight difference in gamma
pass percentage was found between midline and lateralized
tumors. The standard deviation for midline tumors was less
than that for lateralized tumors also the average gamma pass
percentage for midline tumors was greater than that for lat-
eralized tumors. Due to fewer critical structure constraints in
midline tumor cases, the chance for high-pass percentage is
higher. However, for lateralized tumors, a stringent con-
straint causes the MLC movement to become more compli-
cated, which in turn reduces the pass percentage. For some
lateralized tumor cases in which, the partial arc technique is
used for treatment delivery the pass percentage is higher
than the full-arc technique for lateralized tumors since many
critical structures are avoided from the beam; thus, it in-
creases the pass percentage. Even though the difference is
negligible, the pass percentage for lateralized tumors could
be increased by using IMRT technique or partial arc instead
of full arc method.
Conclusion
From our analyses, we found no particular correlation be-
tween the gamma pass percentage for midline tumors and
that for lateralized tumors. Only a marginal difference was
observed in the gamma pass percentage for midline and lat-
eralized tumors. Moreover, the values obtained had no sig-
nificant difference in the t-test. More studies are to be con-
ducted on this topic to make a more generalized conclusion.
This study can be a pilot study in this topic.
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